In this series, we’re looking for the Best in Breed: the company that beats thevery capital intensive and tend to have limited growth potential. The diagnostic companies will likely continue to grow as medical science improves and there are more tests for more conditions; but the market is pretty saturated and none has particularly impressive international growth potential. And that takes us back to the big three: CSL, Cochlear and ResMed. The former has a storied history; the latter a growing market as rising affluence leads to increasing rates of obesity and sleep apnoea.
